Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | XIAP | P98170 | 1/20 | 0.62 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.62 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.57 |
| ▸ | LAP3 | P28838 | 7/20 | 0.56 |
| ▸ | ANPEP | P15144 | 2/20 | 0.56 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.56 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | CPA3 | P15088 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415433 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7436847 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7698421 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL5491058 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2201323 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2029167 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL650855 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3841332 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL1309497 | 0.98 | ALPI (0.60) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL3688220 | 0.98 | ALPI (0.60) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140255523-A1 | Use of Tiliacora Triandra in Cosmetics and Compositions Thereof | AVON PRODUCTS, INC. (US) | 2014-09-11 | — | — | US | claimed |
| EP-2588062-A1 | USE OF TILIACORA TRIANDRA IN COSMETICS AND COMPOSITIONS THEREOF | Avon Products, Inc. (US) | 2013-05-08 | — | — | EP | claimed |
| US-20120003331-A1 | Use of Tiliacora Triandra in Cosmetics and Compositions Thereof | AVON PRODUCTS, INC. (US) | 2012-01-05 | — | — | US | claimed |
| WO-2012002950-A1 | USE OF TILIACORA TRIANDRA IN COSMETICS AND COMPOSITIONS THEREOF | AVON PRODUCTS, INC. (US) | 2012-01-05 | — | — | WO | claimed |
| WO-2011081698-A1 | CGRP COMPOSITIONS AND USES THEREOF | AVON PRODUCTS, INC. (US) | 2011-07-07 | — | — | WO | claimed |
| US-20110159125-A1 | CGRP Compositions and Uses Thereof | AVON PRODUCTS, INC. (US) | 2011-06-30 | — | — | US | claimed |
| US-5516930-A | Intermediates in the production beta aminoalcohols | HOFFMANN-LA ROCHE INC. (US) | 1996-05-14 | — | — | US | claimed |
| JP-11100358-A | — | — | None | — | — | JP | disclosed |
| JP-10182601-A | — | — | None | — | — | JP | disclosed |
| JP-10059909-A | — | — | None | — | — | JP | disclosed |
| EP-2588062-B1 | USE OF TILIACORA TRIANDRA IN COSMETICS AND COMPOSITIONS THEREOF | AVON PROD INC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-9687440-B2 | CGRP compositions and uses thereof | AVON PRODUCTS, INC (US) | 2017-06-27 | — | — | US | disclosed |
| EP-2890359-B1 | DICKKOPF-1 EXPRESSION MODULATING COMPOSITIONS AND USES THEREOF | AVON PROD INC (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-0751145-A2 | HIV-protease inhibitors | Japan Energy Corporation (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-5578730-A | Process for producing β-aminoalcohols compounds | HOFFMANN-LA ROCHE INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5516930-A | Intermediates in the production beta aminoalcohols | HOFFMANN-LA ROCHE INC. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5512682-A | Nitrile compounds useful as intermediates in the production of beta amino alcohols | HOFFMANN-LA ROCHE INC. (US) | 1996-04-30 | — | — | US | disclosed |
| US-5512688-A | METHANESULFONIC ACID(4S,-5S)-4-BENZYL-2-OXO-OXAZOLIDINE -5YLMETHYL ESTER; CHEMICAL INTERMEDIATE FOR FORMING CERTAIN AMINO ACID DERIVATIVES USEFUL AS PHROPHYLAXIS OR TRETAMENT OF RITRO-VIRAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 1996-04-30 | — | — | US | disclosed |
| US-5495025-A | Isoindole compounds which are useful as intermediates | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5455353-A | 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 1995-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003331-A1 | Use of Tiliacora Triandra in Cosmetics and Compositions Thereof | CUTA, COL14A1, COL1A1 | ALPI 1656/4885PKM 3566/4885PTGS1 2494/4885 |
| US-20140255523-A1 | Use of Tiliacora Triandra in Cosmetics and Compositions Thereof | CUTA, COL14A1, COL1A1 | ALPI 1672/4885PKM 3425/4885PTGS1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.